ABGSC acted as Joint Global Coordinator and Joint Bookrunner in the NOK 361 million private placement in Nordic Nanovector ASA

On 23 February 2021, Nordic Nanovector announced the successful placement of 15,878,122 new shares. The private placement was completed at a subscription price of NOK 22.75 per share, which was determined through an accelerated book-building process, for a total transaction size of approximately NOK 361 million.
The Private Placement attracted strong interest from Norwegian, Nordic and international investors and was significantly oversubscribed. Nordic Nanovector is targeting preliminary readout of three-month top-line data from PARADIGME, its pivotal clinical trial with Betalutin, in 2H 2021, a key value inflection point. The proceeds from the private placement are expected to finance the company to the end of 1H 2022, providing an additional at least six months funding to enable the company to maximize shareholder value from PARADIGME.
Further, the net proceeds to the Company from the private placement will be used (i) to conduct pharmacokinetics studies and execute CMC activities required for the regulatory filing, (ii) to initiate the preparatory activities for the confirmatory phase 3 trial and preparation of market launch, and (iii) for general corporate purposes.